OCUL
HealthcareOcular Therapeutix, Inc.
$11.55
$-0.27 (-2.28%)
Jan 5, 2026
Price History (1Y)
Analysis
Ocular Therapeutix, Inc. is a healthcare company operating in the biotechnology industry with a significant market presence. The company has a substantial market capitalization of $2.46 billion and generates revenue of $55.78 million (TTM). Ocular Therapeutix employs 274 individuals. The company's financial health indicates significant challenges in terms of profitability, with negative margins across all categories: gross margin (-246.9%), operating margin (-472.3%), and profit margin (0.0%). Furthermore, the net income is a substantial loss of $249.67 million (TTM). The balance sheet shows that Ocular Therapeutix has cash reserves of $344.77 million and debt of $77.01 million, resulting in a debt-to-equity ratio of 29.82. Valuation metrics suggest a complex situation for the company. With an earnings growth rate not provided (N/A), investors should consider the forward P/E ratio (-7.80) alongside the significant revenue growth decline of -5.7% (YoY).
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $2.46B
- P/E Ratio
- N/A
- 52-Week High
- $16.44
- 52-Week Low
- $5.79
- Avg Volume
- 3.00M
- Beta
- 0.93
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 274